Sage Therapeutics Inc. pushed off questions about potential mergers or acquisitions during its first earnings call since ...

In the fourth quarter, lower sales of BIIB's multiple sclerosis drugs and Spinraza are likely to have been offset by revenues from new drugs.

BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...

Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...

HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...

Sage Therapeutics was in focus after it rejected Biogen's acquisition proposal. Sage Therapeutics stock gained after it announced that its board of directors has rejected the unsolicited, non-binding ...

Securities adjusted its outlook on Sage Therapeutics (NASDAQ:SAGE) shares, with analyst Vamil Divan increasing the price target to $9.00 from the previous $6.00, while maintaining a Neutral rating on ...

Mizuho raised the firm’s price target on Sage Therapeutics (SAGE) to $9 from $6 and keeps a Neutral rating on the shares. The firm reassessed ...

It was a busy week for the biotech sector, with regulatory and pipeline updates. Sage Therapeutics SAGE was in focus after it ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.CBWletoF.js ...